-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Insulin special quantity procurement documents are officially issued!
On November 5, the National Organization for Pharmaceutical Joint Procurement Office issued an announcement on the "National Drug Centralized Procurement Document (Insulin Special) (GY-YD2021-3)" (Guo Lian Cai Zi [2021] No.
3)
.
3)
.
The document shows that the receipt of enterprise application materials will start at 9:00 am on November 26, 2021 (Friday) , and the deadline for submission is 10:00
.
The location is the second floor of the Conference Center of Oriental Beauty Valley Forum Hotel, No.
399 Hupan Road, Fengxian District, Shanghai
.
.
The location is the second floor of the Conference Center of Oriental Beauty Valley Forum Hotel, No.
399 Hupan Road, Fengxian District, Shanghai
.
The types of drugs purchased this time include mealtime human insulin, basal human insulin, premixed human insulin, mealtime insulin analogues, basal insulin analogues, and premixed insulin analogues.
There are 6 purchasing groups in total
.
There are 6 purchasing groups in total
.
The quotation unit of each purchasing group for this centralized insulin purchase is 3ml: 300 units (refill) as the representative product, and the highest effective declaration price is as follows:
The cycle of this centralized insulin procurement is 2 years, calculated from the actual implementation date of the selected results
.
.
Among them, the criteria for determining the product to be selected show that: the declared product meets one of the following rules to be selected, it is eligible to be selected
.
.
Proposed selection rule 1: The declared products in the same procurement group that meet the relevant requirements are sorted according to the "criteria for determining the ranking of declared products", and the final products are determined
.
The maximum number of short-listed products in the same purchase group is determined based on the actual number of products that meet the "eligibility for product declaration"
.
.
The maximum number of short-listed products in the same purchase group is determined based on the actual number of products that meet the "eligibility for product declaration"
.
If the declared price of the shortlisted product is less than 1.
3 times the lowest declared price of the same purchase group, it will be eligible for selection
.
3 times the lowest declared price of the same purchase group, it will be eligible for selection
.
Proposed selection rule 2: If the declared product fails to obtain the proposed selection qualification according to 12.
1, but the declared price has dropped by ≥40% (calculated based on the highest effective declaration price of the corresponding purchase group), it will be eligible for the proposed selection
.
1, but the declared price has dropped by ≥40% (calculated based on the highest effective declaration price of the corresponding purchase group), it will be eligible for the proposed selection
.
In addition, the criteria for determining the ranking of the products to be selected are: 1.
The criteria for determining the ranking of the products to be selected are the same as the "criteria for determining the ranking of declared products"; 2.
In the same procurement group, the company corresponding to the product to be selected is in any province (region, city) According to the medical price and the credit evaluation system of recruitment and procurement, if it is rated as "serious" or "particularly serious", the ranking of the corresponding proposed product will be exchanged with the ranking of the first proposed product that has not been rated above the level of untrustworthiness
.
The criteria for determining the ranking of the products to be selected are the same as the "criteria for determining the ranking of declared products"; 2.
In the same procurement group, the company corresponding to the product to be selected is in any province (region, city) According to the medical price and the credit evaluation system of recruitment and procurement, if it is rated as "serious" or "particularly serious", the ranking of the corresponding proposed product will be exchanged with the ranking of the first proposed product that has not been rated above the level of untrustworthiness
.
At the same time, the Joint Procurement Office issued a notice on the implementation of the sixth batch of national-organized centralized drug procurement (insulin special) drug information filling work, requiring that this centralized procurement product obtain a valid domestic registration approval document before November 14, 2021 (inclusive) The quality of the listed drugs meets the standards of the relevant national departments and is produced in accordance with the requirements of the relevant departments
.
.
Insulin special quantity procurement documents are officially issued!
On November 5, the National Organization for Pharmaceutical Joint Procurement Office issued an announcement on the "National Drug Centralized Procurement Document (Insulin Special) (GY-YD2021-3)" (Guo Lian Cai Zi [2021] No.
3)
.
3)
.
The document shows that the receipt of enterprise application materials will start at 9:00 am on November 26, 2021 (Friday) , and the deadline for submission is 10:00
.
The location is the second floor of the Conference Center of Oriental Beauty Valley Forum Hotel, No.
399 Hupan Road, Fengxian District, Shanghai
.
.
The location is the second floor of the Conference Center of Oriental Beauty Valley Forum Hotel, No.
399 Hupan Road, Fengxian District, Shanghai
.
The types of drugs purchased this time include mealtime human insulin, basal human insulin, premixed human insulin, mealtime insulin analogues, basal insulin analogues, and premixed insulin analogues.
There are 6 purchasing groups in total
.
There are 6 purchasing groups in total
.
The quotation unit of each purchasing group for this centralized insulin purchase is 3ml: 300 units (refill) as the representative product, and the highest effective declaration price is as follows:
The cycle of this centralized insulin procurement is 2 years, calculated from the actual implementation date of the selected results
.
.
Among them, the criteria for determining the product to be selected show that: the declared product meets one of the following rules to be selected, it is eligible to be selected
.
.
Proposed selection rule 1: The declared products in the same procurement group that meet the relevant requirements are sorted according to the "criteria for determining the ranking of declared products", and the final products are determined
.
The maximum number of short-listed products in the same purchase group is determined based on the actual number of products that meet the "eligibility for product declaration"
.
.
The maximum number of short-listed products in the same purchase group is determined based on the actual number of products that meet the "eligibility for product declaration"
.
If the declared price of the shortlisted product is less than 1.
3 times the lowest declared price of the same purchase group, it will be eligible for selection
.
3 times the lowest declared price of the same purchase group, it will be eligible for selection
.
Proposed selection rule 2: If the declared product fails to obtain the proposed selection qualification according to 12.
1, but the declared price has dropped by ≥40% (calculated based on the highest effective declaration price of the corresponding purchase group), it will be eligible for the proposed selection
.
1, but the declared price has dropped by ≥40% (calculated based on the highest effective declaration price of the corresponding purchase group), it will be eligible for the proposed selection
.
In addition, the criteria for determining the ranking of the products to be selected are: 1.
The criteria for determining the ranking of the products to be selected are the same as the "criteria for determining the ranking of declared products"; 2.
In the same procurement group, the company corresponding to the product to be selected is in any province (region, city) According to the medical price and the credit evaluation system of recruitment and procurement, if it is rated as "serious" or "particularly serious", the ranking of the corresponding proposed product will be exchanged with the ranking of the first proposed product that has not been rated above the level of untrustworthiness
.
The criteria for determining the ranking of the products to be selected are the same as the "criteria for determining the ranking of declared products"; 2.
In the same procurement group, the company corresponding to the product to be selected is in any province (region, city) According to the medical price and the credit evaluation system of recruitment and procurement, if it is rated as "serious" or "particularly serious", the ranking of the corresponding proposed product will be exchanged with the ranking of the first proposed product that has not been rated above the level of untrustworthiness
.
At the same time, the Joint Procurement Office issued a notice on the implementation of the sixth batch of national-organized centralized drug procurement (insulin special) drug information filling work, requiring that this centralized procurement product obtain a valid domestic registration approval document before November 14, 2021 (inclusive) The quality of the listed drugs meets the standards of the relevant national departments and is produced in accordance with the requirements of the relevant departments
.
.
Insulin special quantity procurement documents are officially issued!
Insulin special quantity procurement documents are officially issued! On November 5, the National Organization for Pharmaceutical Joint Procurement Office issued an announcement on the "National Drug Centralized Procurement Document (Insulin Special) (GY-YD2021-3)" (Guo Lian Cai Zi [2021] No.
3)
.
3)
.
The document shows that the receipt of enterprise application materials will start at 9:00 am on November 26, 2021 (Friday) , and the deadline for submission is 10:00
.
The location is the second floor of the Conference Center of Oriental Beauty Valley Forum Hotel, No.
399 Hupan Road, Fengxian District, Shanghai
.
Enterprise business enterprise.
The location is the second floor of the Conference Center of Oriental Beauty Valley Forum Hotel, No.
399 Hupan Road, Fengxian District, Shanghai
.
The types of drugs purchased this time include mealtime human insulin, basal human insulin, premixed human insulin, mealtime insulin analogues, basal insulin analogues, and premixed insulin analogues.
There are 6 purchasing groups in total
.
Procurement Procurement ProcurementThere are 6 purchasing groups in total
.
The quotation unit of each purchasing group for this centralized insulin purchase is 3ml: 300 units (refill) as the representative product, and the highest effective declaration price is as follows:
The cycle of this centralized insulin procurement is 2 years, calculated from the actual implementation date of the selected results
.
.
Among them, the criteria for determining the product to be selected show that: the declared product meets one of the following rules to be selected, it is eligible to be selected
.
.
Proposed selection rule 1: The declared products in the same procurement group that meet the relevant requirements are sorted according to the "criteria for determining the ranking of declared products", and the final products are determined
.
The maximum number of short-listed products in the same purchase group is determined based on the actual number of products that meet the "eligibility for product declaration"
.
.
The maximum number of short-listed products in the same purchase group is determined based on the actual number of products that meet the "eligibility for product declaration"
.
If the declared price of the shortlisted product is less than 1.
3 times the lowest declared price of the same purchase group, it will be eligible for selection
.
3 times the lowest declared price of the same purchase group, it will be eligible for selection
.
Proposed selection rule 2: If the declared product fails to obtain the proposed selection qualification according to 12.
1, but the declared price has dropped by ≥40% (calculated based on the highest effective declaration price of the corresponding purchase group), it will be eligible for the proposed selection
.
1, but the declared price has dropped by ≥40% (calculated based on the highest effective declaration price of the corresponding purchase group), it will be eligible for the proposed selection
.
In addition, the criteria for determining the ranking of the products to be selected are: 1.
The criteria for determining the ranking of the products to be selected are the same as the "criteria for determining the ranking of declared products"; 2.
In the same procurement group, the company corresponding to the product to be selected is in any province (region, city) According to the medical price and the credit evaluation system of recruitment and procurement, if it is rated as "serious" or "particularly serious", the ranking of the corresponding proposed product will be exchanged with the ranking of the first proposed product that has not been rated above the level of untrustworthiness
.
Medicine Medicine MedicineThe criteria for determining the ranking of the products to be selected are the same as the "criteria for determining the ranking of declared products"; 2.
In the same procurement group, the company corresponding to the product to be selected is in any province (region, city) According to the medical price and the credit evaluation system of recruitment and procurement, if it is rated as "serious" or "particularly serious", the ranking of the corresponding proposed product will be exchanged with the ranking of the first proposed product that has not been rated above the level of untrustworthiness
.
At the same time, the Joint Procurement Office issued a notice on the implementation of the sixth batch of national-organized centralized drug procurement (insulin special) drug information filling work, requiring that this centralized procurement product obtain a valid domestic registration approval document before November 14, 2021 (inclusive) The quality of the listed drugs meets the standards of the relevant national departments and is produced in accordance with the requirements of the relevant departments
.
Drugs Drugs Drugs Standard Standard Standard .
